Exicure (XCUR) Stock Price, News & Analysis

Company Overview

Exicure, Inc. (NASDAQ: XCUR) is a clinical‐stage biotechnology company specializing in the development of innovative spherical nucleic acid (SNA) therapeutics. The company’s proprietary SNA platform is designed to enhance cellular uptake and stability of nucleic acids, enabling targeted treatment of neurological disorders, oncology indications, and immuno‐inflammatory diseases. By leveraging its unique chemistry and nanoparticle design, Exicure aims to overcome traditional obstacles in nucleic acid delivery and broaden the therapeutic potential of gene regulation technologies.

The company’s pipeline includes multiple research and development programs spanning distinct disease areas. Lead candidates are advancing through preclinical and early clinical studies, focusing on activation of immune pathways such as the STING (stimulator of interferon genes) and RIG‐I (retinoic acid–inducible gene I) signaling cascades for cancer immunotherapy. In parallel, Exicure is exploring neurology assets targeting central nervous system disorders through direct delivery to the brain, with the goal of addressing conditions that have historically lacked effective treatments.

Founded in 2016 and headquartered in Chicago, Exicure was built upon technology originally developed at Northwestern University’s International Institute for Nanotechnology. The company has established strategic partnerships and research collaborations with global pharmaceutical firms to accelerate its SNA programs. Its operations are concentrated in the United States, with research facilities in Illinois and collaborative research sites in Europe and Asia supporting discovery and translational efforts.

Exicure’s leadership team features Chief Executive Officer James “Jim” Rogers, who brings extensive experience in biopharmaceutical development, and Chief Financial Officer Heather Lin, an expert in capital markets and corporate finance. The executive team is supported by a board of directors comprised of seasoned biotech entrepreneurs and academic leaders. Together, they guide the company’s strategic growth, regulatory planning, and clinical execution to advance SNA-based therapeutics toward commercialization.

Key Stats

• Today's Range: $6.85 to $7.64
• 50-Day Range: $5.55 to $11.86
• 52-Week Range: $1.44 to $36.00
• Volume: 13,478 shs
• Average Volume: 575,945 shs
• Market Capitalization: $46.01 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Exicure Stock Analysis - MarketRank™

Exicure scored higher than 27% of companies evaluated by MarketBeat, and ranked 800th out of 920 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Exicure.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Exicure is -2.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Exicure is -2.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Exicure has a P/B Ratio of 6.81. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.73% of the float of Exicure has been sold short.

Short Interest Ratio / Days to Cover

Exicure has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Exicure has recently decreased by 40.79%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Exicure does not currently pay a dividend.

Dividend Growth

Exicure does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.7 / 5
• Environmental Score: -0.67

Percentage of Shares Shorted

0.73% of the float of Exicure has been sold short.

Short Interest Ratio / Days to Cover

Exicure has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Exicure has recently decreased by 40.79%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

Search Interest

Only 1 people have searched for XCUR on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

1 people have added Exicure to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Exicure insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 3.90% of the stock of Exicure is held by insiders.

Percentage Held by Institutions

42.82% of the stock of Exicure is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

XCUR Stock Analysis - Frequently Asked Questions

How have XCUR shares performed this year?

Exicure's stock was trading at $13.67 at the beginning of 2025. Since then, XCUR shares have decreased by 44.2% and is now trading at $7.6250.

How were Exicure's earnings last quarter?

Exicure, Inc. (NASDAQ:XCUR) posted its quarterly earnings data on Friday, June, 27th. The company reported ($0.45) earnings per share for the quarter.

When did Exicure's stock split?

Exicure shares reverse split on Tuesday, August 27th 2024.The 1-5 reverse split was announced on Monday, August 26th 2024. The number of shares owned by shareholders was adjusted after the market closes on Monday, August 26th 2024. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split.

How do I buy shares of Exicure?

Shares of XCUR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Exicure own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Exicure investors own include Sorrento Therapeutics (SRNE), Allena Pharmaceuticals (ALNA), Tesla (TSLA), Meta Platforms (META), NIO (NIO), Viking Therapeutics (VKTX) and Energy Transfer (ET).

Company Calendar

• Last Earnings: 6/27/2025
• Today: 7/10/2025
• Next Earnings (Estimated): 8/11/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:XCUR
• CIK: 1698530
• Web: www.exicuretx.com
• Phone: (847) 673-1700
• Fax: N/A
• Employees: 50
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($3.82)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$9.70 million
• Net Margins: N/A
• Pretax Margin: -1,938.60%
• Return on Equity: -219.60%
• Return on Assets: -82.03%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.91
• Quick Ratio: 2.91

Sales & Book Value

• Annual Sales: $500 thousand
• Price / Sales: 96.38
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.12 per share
• Price / Book: 6.81

Miscellaneous

• Outstanding Shares: 6,320,000
• Free Float: 6,072,000
• Market Cap: $48.19 million
• Optionable: Not Optionable
• Beta: 3.57